Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22430408 | 0.83 | RIPK1 (0.46) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL30165675 | 0.81 | DAO (0.49) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL857442 | 0.81 | DAO (0.49) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL18511075 | 0.80 | RIPK1 (0.44) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL29587438 | 0.80 | RIPK1 (0.48) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL22025096 | 0.79 | RIPK1 (0.39) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL12333 | 0.79 | DAO (0.53) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL22537693 | 0.78 | RIPK1 (0.55) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL22077190 | 0.78 | RIPK1 (0.38) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL30376472 | 0.77 | RIPK1 (0.46) | RIPK1DAOCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2023-10-05 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| EP-2069341-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | Glaxo Group Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008145688-A2 | PYRROLOPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008034860-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | RIPK1 120/4885DAO 3932/4885CCNB2 704/4885 |
| US-20240239776-A1 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LPAR1 | RIPK1 4510/4885DAO 361/4885CCNB2 2188/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | RIPK1 2828/4885DAO 173/4885CCNB2 2412/4885 |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | RIPK1 2551/4885DAO 1848/4885CCNB2 417/4885 |
| US-20230312511-A1 | SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE | SLC6A3, DRD3, DRD2 | RIPK1 1205/4885DAO 1418/4885CCNB2 2527/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | RIPK1 120/4885DAO 3932/4885CCNB2 704/4885 |
| US-11787798-B2 | Aryl piperidines as monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | RIPK1 4369/4885DAO 1501/4885CCNB2 3910/4885 |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | RIPK1 4431/4885DAO 583/4885CCNB2 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.